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Each year when I teach my genetics students about Knud-
sen’s two-hit hypothesis and retinoblastoma, I get the
same question: when somebody inherits an RB1mutation,
why do tumors mostly occur in the retina? This is exactly
the question that Xu et al. explore in their recent paper.
The answer appears to be that, although loss of Rb is the
key initiating event in retinoblastoma, it is the particular
cellular environment in which this occurs that makes the
difference in tumor formation. Retinoblastoma cells
express markers of cone precursors but not those of other
retinal cell types, implicating the cones as being the cells
in which retinoblastomas arise. What makes these cells
vulnerable to transformation when Rb is lost? The parti-
cular signaling circuitry expressed in these cells, which
naturally includes high levels of MDM2 and N-Myc, is
key. These proteins promote proliferation and dampen
the ARF-mediated apoptotic response that is induced by
Rb loss, thereby supporting oncogenesis. Knock-down of
expression of either protein decreases proliferation of reti-
noblastoma cell lines. Overall, this work highlights parti-
cular signaling pathways that appear to be central to the
development of retinoblastomas speciﬁcally in cone cells.
This leads me to the answer I have for my students this
year: not only do you have to have those ﬁrst two hits in
RB1 to get a tumor, but the hits also have to occur in the
right cellular environment to foster its proliferation.
Xu et al. (2009). Retinoblastoma has properties of a cone
precursor tumor and depends upon cone-speciﬁc MDM2
signaling. Cell 137, 1018–1031. 10.1016/j.cell.2009.03.051.
Immune Response to Gene Therapy: Beyond
the Target Protein
In considering gene therapy for genetic diseases, one of the
things that people have worried about is that the target
protein will be recognized as foreign and eliminated from
the body. In a recent clinical trial of gene therapy for
hemophilia B that used an adeno-associated virus as the
vector, this seemed to occur in one of the nine patients.
In this patient, Factor IX (F9) levels returned to baseline
at the same time that the patient’s liver enzymes became
elevated, suggesting that liver cells transduced with the
vector were being cleared by cytotoxic T lymphocytes(CTLs). Although this immune response might have been
directed at the vector itself, Li et al. believed the kinetics
of liver cell damage and loss of F9 suggest the CTLs were
directed against F9 epitopes, despite the fact that these
CTLs were not found. They explored their ideas in mice ex-
pressing the human MHC I allele that was found in this
patient. When a vector expressing F9 is delivered to these
mice, CTLs are generated—not against the primary F9
open reading frame, but rather against a cryptic epitope
derived from an alternative reading frame of F9. Why
this cryptic epitope is expressed isn’t yet clear—maybe
a regulatory element got lost or added in the making of
the cDNA cassette—but it does seem to direct CTLs to
transduced hepatocytes and thus reduce the levels of F9
achieved in the mice. This work is a cautionary tale for
researchers pursuing gene therapy; the good news is that
F9 codon optimization that eliminated the cryptic epitope
allowed them to avoid CTL-mediated elimination of trans-
duced hepatocytes in their model.
Li et al. (2009). Cellular immune response to cryptic epitopes
during therapeutic gene transfer. Proc. Natl. Acad. Sci. Pub-
lished online June 16, 2009. 10.1073/pnas.0902269106.
Studying Human Evolution in Mice
Could a single gene be the key to human language? FOXP2
has been implicated in language development in several
different ways, including the identiﬁcation of gene disrup-
tions in people with speech-language impairment and the
fact that positive selection appears to have led to the ﬁxa-
tion of two amino acid substitutions in the human version
of FOXP2 after the human lineage separated from chim-
panzees. To study the role of the human form of FOXP2,
Enard et al. put a humanized version of the Foxp2 gene
into mice. Lo and behold, despite differing from their
wild-type littermates by only two amino acids in this one
gene, pups with the humanized Foxp2 vocalize at signiﬁ-
cantly lower frequencies than their wild-type littermates.
Extensive characterization of these mice also revealed
that they exhibit decreased exploratory behavior and
decreased dopamine concentrations in the brain. In the
basal ganglia, they also have medium spiny neurons with
longer dendrites and increased synaptic plasticity. Oppo-
site effects are observed in mice that express lower-than-
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humanized gene are not simply reducing gene function.
Do the changes to the vocalization frequency in these
mice result from the differences documented in the basal
ganglia? Circuits in this region of the brain have been
implicated in speech and language, but further work is
needed for researchers to determine whether this is the
case and to further explore whether these changes were
at least partly responsible for the development of human
language.
Enard et al. A humanized version of Foxp2 affects cortico-
basal ganglia circuits in mice. Cell 137, 961–971. 10.1016/
j.cell.2009.03.041.
Better Predictions of miRNA Targets
Although microRNAs (miRNAs) are clearly important for
the regulationof gene expression, the fact that they interact
with their targets at as few as six nucleotides means that it
has been difﬁcult to identify the true targets of a particular
miRNA. Several predictive algorithms have been designed
to pull out these targets, but their predictions don’t always
agree, and they are plagued by false positives. Chi et al. took
an experimental approach to miRNA target prediction.
They have been working on a high-throughput method
called HITS-CLIP, in which RNAs that have been cross-
linked to a protein are immunoprecipitated and sequenced.
In mouse brain, they immunoprecipitated argonaute to
identify the RNAs crosslinked to this protein, which is
involved in miRNA-mediated gene regulation. Two pools
of RNA are pulled down: one corresponding to miRNAs
and one to themRNA targets. They could then try tomatch
up the Ago-mRNA footprint with the miRNA seed se-
quences to predict true miRNA binding sites. Compared
to bioinformatic approaches, this experimental method
has increased sensitivity and speciﬁcity for target prediction
and should be useful as a generalmethodology for the iden-
tiﬁcation of meaningful miRNA-mRNA interactions.
Chi et al. (2009). Argonaute HITS-CLIP decodes miRNA-
mRNA interaction maps. Nature, published online June 17,
2009. 10/1038/nature08170.4 The American Journal of Human Genetics 85, 3–5, July 10, 2009Using Genetics in a Randomized Controlled Trial
Elevated lipoprotein(a) levels are associated with heart
attack, but whether this circumstantial evidence means
there is a causal association has been a topic of discus-
sion. We don’t yet have a way to modulate lipoprotein(a)
levels, so we can’t ﬁgure out the causality of association
in a typical randomized controlled trial. Instead,
Kamstrup et al. used Mendelian randomization to study
lipoprotein(a)’s effect on risk of heart attack. The basic
idea is this: because alleles are randomly assorted to
offspring, you can set up a pseudo-randomized con-
trolled trial based on genotypes. Any other confounders
that you don’t measure should also be randomly assorted
to the groups, so in this way you should be able to study
the effect of your trait of interest. Through this type of
study design, Kamstrup et al. show that the kringle IV
type 2 polymorphism (KIV-2) in the LPA gene, which is
the known polymorphism that has the biggest effect
on lipoprotein(a) levels, is associated with a risk of heart
attack in three population-based studies from Denmark.
In the same samples, they conﬁrmed that lipoprotein(a)
levels themselves are associated with a risk of heart attack
and that adjustment for the KIV-2 genotype attenuates
these risks. In the Copenhagen City Heart Study sample,
a doubling of plasma lipoprotein(a) levels gives a hazard
ratio for heart attack of 1.08; in comparison, a doubling
of the genetically elevated lipoprotein(a) levels in
Kamstrup et al.’s sample gives a hazard ratio of 1.22.
The authors argue that this latter estimate might be
more accurate because genetically based differences in
lipoprotein(a) levels last a lifetime, whereas single
measurements of lipoprotein(a) are a snapshot of the
overall picture. Regardless of the exact risk, these results
cement the causal role of lipoprotein(a) in the risk of
heart attack. The next step is ﬁguring out how to modify
these risks.
Kamstrup et al. (2009). Genetically elevated lipoprotein(a)
and increased risk of myocardial infarction. JAMA 301,
2331–2339.This Month in Our Sister Journals
Array-CGH for Diagnosis of Mitochondrial
Disorders
Molecular diagnosis of mitochondrial disorders can be
quite challenging. Not only can mutations to the mito-
chondrial DNA (mtDNA) itself be the problem, but they
can also be found in nuclear genes that encode compo-
nents of the mitochondria or that are responsible for
synthesis of mtDNA. Chinault et al. have streamlined theprocess for analysis of mtDNA deletion and depletion
through the development of a custom oligonucleotide
array that includes coverage for the entire mitochondrial
genome as well as ~150 relevant nuclear genes. A critical
aspect of this type of array is that the reference sample
must be matched for tissue and age because mtDNA copy
number varies between tissues and with age. If proper
attention is not paid to the reference, depletions ofmtDNA
can be missed. Not only can this array be used to detect
the size and location of a deletion in any of these regions,
but it can also be used to estimate the percentage of heter-
oplasmy for a mtDNA deletion. This type of approach
should reduce the number of steps it takes to accurately
ﬁnd and characterize deletions that cause mitochondrial
disorders.
Chinault et al. (2009). Application of dual-genome oligonu-
cleotide array-based comparative genomic hybridization to the
molecular diagnosis of mitochondrial DNA deletion and deple-
tion syndromes. Genetics in Medicine 11, 518–526.
Is Epigenetics to Blame for Missing Heritability?
Genome-wide association studies have given us insight
into complex disease, but the risk variation that we have
so far pulled out from these studies does not come
anywhere near to explaining the full heritability of most
of these traits. Some argue that rare genetic variation isgoing to be the next frontier for research in complex traits.
Monty Slatkin decided to explore whether epigenetic
changes could explain this problem of missing heritability.
In the ﬁrst step toward this goal, he developed a simple
framework to model epigenetic inheritance. Because the
rate of gain and loss of epigenetic changes is likely to be
higher than that of mutations, close relatives are less likely
to share these changes than is implied by their relatedness.
This makes it unlikely that inherited epigenetic changes
account for the missing heritability in complex disease,
unless these changes are much more common than muta-
tions or they have a much larger effect on disease risk.
Before we can fully tease this apart, we need better esti-
mates of the rate of epigenetic change and how long these
changes persist.
Slatkin (2009). Epigenetic inheritance and the missing herit-
ability problem. Genetics 182, 845–850. Published online
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